Targeting HOX/PBX dimers in cancer

Richard Morgan; Mohamed El-Tanani; Keith D. Hunter; Kevin J. Harrington; Hardev S. Pandha

doi:10.18632/oncotarget.15971

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Targeting HOX/PBX dimers in cancer

Richard Morgan _, Mohamed El-Tanani, Keith D. Hunter, Kevin J. Harrington and Hardev S. Pandha

PDF | HTML | How to cite

Oncotarget. 2017; 8:32322-32331. https://doi.org/10.18632/oncotarget.15971

Metrics: PDF 2908 views | HTML 5814 views | ?

Abstract

Richard Morgan1, Mohamed El-Tanani1, Keith D. Hunter2, Kevin J. Harrington3 and Hardev S. Pandha4

1 Institute of Cancer Therapeutics, Faculty of Life Sciences, University of Bradford, Bradford, UK

2 Unit of Oral and Maxillofacial Pathology, School of Clinical Dentistry, University of Sheffield, Sheffield, UK

3 Targeted Therapy Team, Chester Beatty Laboratories, The Institute of Cancer Research, London, UK

4 Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK

Correspondence to:

Richard Morgan, email:

Keywords: HOX, PBX, HXR9, targeted therapy, biomarker

Received: December 08, 2016 Accepted: February 23, 2017 Published: March 07, 2017

Abstract

The HOX and PBX gene families encode transcription factors that have key roles in establishing the identity of cells and tissues in early development. Over the last 20 years it has become apparent that they are also dysregulated in a wide range of solid and haematological malignancies and have a predominantly pro-oncogenic function. A key mode of transcriptional regulation by HOX and PBX proteins is through their interaction as a heterodimer or larger complex that enhances their binding affinity and specificity for DNA, and there is growing evidence that this interaction is a potential therapeutic target in malignancies that include prostate, breast, renal, ovarian and lung cancer, melanoma, myeloma, and acute myeloid leukaemia. This review summarizes the roles of HOX and PBX genes in cancer and assesses the therapeutic potential of HOX/PBX dimer inhibition, including the availability of biomarkers for its application in precision medicine.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15971

Publication Alerts

Reviews:

Targeting HOX/PBX dimers in cancer

Abstract